2m 2m 2m 2m 2m 2m 2m
Ultragenyx Pharm (RARE)
NASDAQ
$29.02-$0.009 (-0.03%)
Price as of Jun 23, 2026 3:03 PM EDT- $2.9BMarket Cap
- -21.18%1-Year Change
- BiotechnologyIndustry
Ultragenyx Pharm (RARE)
$29.02-$0.009 (-0.03%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 369.0M -34.13% | 560.2M +29.01% | 434.2M +19.52% | 363.3M +3.39% | |
Cost of Revenue | 109.0M +42.06% | 76.7M +69.72% | 45.2M +59.64% | 28.3M +76.91% | |
Gross Profit | 260.0M -46.23% | 483.5M +24.28% | 389.0M +16.13% | 335.0M -0.12% | |
Sales and Marketing Expense | 349.0M +8.52% | 321.6M +3.81% | 309.8M +11.38% | 278.1M +26.44% | |
Research and Development Expense | -1.0M -99.86% | -697.9M +7.62% | -648.4M -8.12% | -705.8M +41.97% | |
Depreciation and Amortization Expense | 35.0M -1.53% | 35.5M +36.67% | 26.0M +42.73% | 18.2M +37.62% | |
Total Operating Expenses | 1.2B +10.20% | 1.1B +9.24% | 1.0B -0.87% | 1.0B +38.07% | |
Operating Profit | -535.0M -0.18% | -536.0M -5.84% | -569.2M -12.28% | -648.9M +69.99% | |
Interest Income | 25.0M -31.52% | 36.5M +36.79% | 26.7M +141.00% | 11.1M +474.38% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 25.0M -31.52% | 36.5M +36.79% | 26.7M +141.00% | 11.1M +474.38% | |
Total Nonoperating Income and Expense | 1.0M +125.23% | -4.0M +1,075.96% | -337,000 -78.48% | -1.6M -7.17% | |
Income before Taxes | -571.0M +0.60% | -567.6M -6.72% | -608.5M -13.29% | -701.7M +54.91% | |
Income Taxes | 4.0M +150.47% | 1.6M +187.51% | -1.8M -132.04% | 5.7M +445.59% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -575.0M +1.02% | -569.2M -6.17% | -606.6M -14.25% | -707.4M +55.81% | |
Net Income from Continuing Operations Applicable to Common | -571.0M +0.60% | -567.6M -6.72% | -608.5M -13.29% | -701.7M +54.91% | |
Basic EPS and Net Income | -5.83 -7.31% | -6.29 -23.76% | -8.25 -18.48% | -10.12 +51.04% | |
Diluted EPS and Net Income | -5.83 -7.31% | -6.29 -23.76% | -8.25 -18.48% | -10.12 +51.04% | |
Basic Weighted Average Shares | 98.6M +8.90% | 90.5M +23.11% | 73.5M +5.19% | 69.9M +3.13% | |
Diluted Weighted Average Shares | 98.6M +8.90% | 90.5M +23.11% | 73.5M +5.19% | 69.9M +3.13% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 421.0M +142.33% | 173.7M -18.66% | 213.6M +60.66% | 132.9M -56.78% | |
Short-Term Investments | 259.0M -40.64% | 436.3M +19.99% | 363.6M -40.86% | 614.8M +42.12% | |
Cash and Cash Equivalents and Short-Term Investments | 680.0M +11.47% | 610.0M +5.69% | 577.2M -22.81% | 747.8M +1.02% | |
Total Current Assets | 951.0M +16.38% | 817.1M +11.60% | 732.2M -17.16% | 883.9M +3.19% | |
Accumulated Depreciation | 136.0M +20.91% | 112.5M +34.87% | 83.4M +31.59% | 63.4M +26.67% | |
Property and Plant and Equipment and Net | 244.0M -8.25% | 265.9M -8.48% | 290.6M +11.87% | 259.7M +83.88% | |
Total Long-Term Assets | 60.0M -4.28% | 62.7M +8.66% | 57.7M +242.43% | 16.8M -18.06% | |
Total Assets | 1.5B +1.90% | 1.5B +0.83% | 1.5B -3.52% | 1.5B +1.51% | |
Income Taxes Payable | 30.0M -0.19% | 30.1M 0.00% | 30.1M -5.08% | 31.7M -4.92% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 384.0M +11.58% | 344.2M +22.72% | 280.4M +7.36% | 261.2M +44.02% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 20.0M +17.08% | 17.1M +39.96% | 12.2M +153.22% | 4.8M +379.60% | |
Total Liabilities | 1.6B +29.31% | 1.2B +2.10% | 1.2B +1.90% | 1.2B +98.88% | |
Retained Earnings | -4.5B +14.54% | -4.0B +16.80% | -3.4B +21.81% | -2.8B +34.12% | |
Total Stockholders Equity | -80.0M -131.34% | 255.3M -7.30% | 275.4M -21.87% | 352.5M -61.79% | |
Total Shares Outstanding | 96.6M +4.45% | 92.5M +12.35% | 82.3M +17.26% | 70.2M +1.23% | |
Cash Flow | |||||
Cash from Operating Activities | -466.0M +12.51% | -414.2M -12.77% | -474.8M +24.80% | -380.5M +12.33% | |
Capital Expenditures | 6.0M -19.90% | 7.5M -83.08% | 44.3M -61.88% | 116.1M +58.87% | |
Cash from Investing Activities | 236.0M +1,428.23% | -17.8M -110.58% | 168.0M +157.60% | -291.7M +49.28% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 478.0M +19.73% | 399.2M +2.86% | 388.1M -22.56% | 501.2M +322.77% | |
Financials Ratio | |||||
Gross Margin | 70.46% -18.36% | 86.30% -3.67% | 89.59% -2.84% | 92.21% -3.39% | |
Operating Margin | -144.99% +51.55% | -95.67% -27.01% | -131.08% -26.61% | -178.60% +64.41% | |
Return on Assets | -37.89% -0.34% | -38.02% -4.86% | -39.96% -13.36% | -46.12% +66.69% | |
Return on Equity | -656.03% +205.84% | -214.50% +11.01% | -193.23% +74.13% | -110.96% +153.80% | |
Revenue Growth | -34.13% -217.66% | 29.01% +48.63% | 19.52% +475.30% | 3.39% -88.56% | |
Current Ratio | 2.48 +4.31% | 2.37 -9.06% | 2.61 -22.84% | 3.38 -28.35% | |
Cash Ratio | 1.10 +117.19% | 0.50 -33.72% | 0.76 +49.63% | 0.51 -69.99% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow